Search

Your search keyword '"Pelton, Matt"' showing total 21 results
Start Over Author "Pelton, Matt"
21 results on '"Pelton, Matt"'

2. How accounting leaders can embrace ESG for a strategic advantage: Working with an oversight committee, building a road map, benchmarking, and focusing on quality can help businesses guide their ESG strategy.

Author

Niehaus, Drew and Pelton, Matt

Subjects
Sustainable development -- Laws, regulations and rules, Corporate governance -- Laws, regulations and rules -- Social aspects -- Environmental aspects, Corporate social responsibility -- Laws, regulations and rules -- Environmental aspects, Disclosure of information -- Laws, regulations and rules, Leadership styles -- Methods, Socially responsible investments -- Management -- Laws, regulations and rules, Accounting firms -- Management -- Laws, regulations and rules, Government regulation, Company business management
Abstract

The CFO ... can bring a measured perspective on the ways companies can unlock financial value and mitigate enterprise risk through ESG investments. Not that long ago, the integration of [...]

Published
2023

7. LONG TERM EVALUATION OF THE SAFETY AND EFFICACY OF ENDOSCOPIC DIRECT TRANSGASTRIC ERCP (EDGE)

Author

Tyberg, Amy, primary, Sarkar, Avik, additional, Shahid, Haroon, additional, Miller, Dillon, additional, Pelton, Matt, additional, Vazquez-Sequeiros, Enrique, additional, Gornals, Joan, additional, Gjeorgjievski, Mihajlo, additional, Abdelqader, Abdelhai, additional, Tarnasky, Paul, additional, Braun, David, additional, Lee, David, additional, Chalikonda, Divya, additional, Bilello, Justin, additional, Schlachterman, Alexander, additional, Kumar, Anand, additional, Chiang, Austin, additional, Kowalski, Thomas, additional, Loren, David, additional, Zitun, Mohamed, additional, Thakkar, Shyam, additional, Kedia, Prashant, additional, Gaidhane, Monica, additional, and Kahaleh, Michel, additional

Published
2023
Full Text
View/download PDF

8. COMPLICATIONS OF EDGE PROCEDURE BASED ON LOCATION OF THE DISTAL FLANGE IN THE EXCLUDED STOMACH

Author

Shinn, Brianna, primary, Boortalary, Tina, additional, Chalikonda, Divya, additional, Chowdhury, Salil, additional, Winte, Maria, additional, Patel, Akash, additional, Shrigiriwar, Apurva, additional, Assefa, Redeat, additional, Bejjani, Michael, additional, Khashab, Mouen, additional, Tyberg, Amy, additional, Shahid, Haroon, additional, Sarkar, Avik, additional, Gaidhane, Monica, additional, Pelton, Matt, additional, Miller, Dillon, additional, Kahaleh, Michel, additional, Khara, Harshit, additional, Makar, Michael, additional, Confer, Bradley, additional, Sangwan, Vikas, additional, Diehl, David, additional, Kedia, Prashant, additional, Oza, Veeral, additional, Jones, Wesley, additional, Taunk, Pushpak, additional, KAMAL, F.A.I.S.A.L., additional, Chiang, Austin, additional, Kumar, Anand, additional, Schlachterman, Alexander, additional, Loren, David, additional, and Kowalski, Thomas, additional

Published
2023
Full Text
View/download PDF

9. Race and Ethnic Representation in Crohn's Disease Trials of Biologic and Small Molecule Medications: A Systematic Review and Meta-analysis.

Author

Pelton, Matt, Ssentongo, Paddy, Sun, Ashley, Groff, Destin, Dalessio, Shannon, and Clarke, Kofi

Abstract

Background and Aims Randomised controlled trials historically under-represent marginalised racial and ethnic populations. As incidence and prevalence of Crohn's disease in these groups rise, it is important to characterise their inclusion in randomised controlled trials on first-line and pipe-line medications. Methods PubMed was searched systematically for randomised controlled trials of biologic and small molecule inhibitor [SMI] medications, with a primary outcome related to efficacy following PRISMA guidelines. We used descriptive statistics to summarise demographic variables and meta-regression analyses to estimate temporal trends in racial inclusion. Results More than a half of trials did not report any racial/ethnic demographics [53.7%] and several reported racial demographics for only one race [20.9%]. When racial data were reported, Whites made up 90.2% of participants. Percentages of Black, Asian, Native American/Pacific Islander, and participants considered 'Other' averaged 2.9%, 11.6%, 0.5%, and 1.6% out of the total sample sizes of 3901, 3742, 828 and 4027, respectively. Proportional representation of White participants decreased over time [ p  <0.01] and proportional representation of Asian participants increased over time [ p  = 0.047]. In ordinal logistic regression, mean year of trial enrolment significantly increased the number of racial groups reported [ p  <0.001]. Conclusions Half of published randomised controlled trials in Crohn's disease contain no racial or ethnic demographics, and the remaining often only have limited inclusion of Black, Native American/Pacific Islander, and Hispanic patients. Further work should characterise representation in observational and prospective trials. Researchers should work to: 1] increase reporting of racial and ethnic demographics; and 2] improve recruitment and retention of marginalised populations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results